Sort   by:  
 Page size 
ProteomicsUnraveling the dual roles of MICAL2 in skeletal muscle physiology and fusion negative rhabdomyosarcoma tumor progression
Rhabdomyosarcoma (RMS) is a prevalent soft tissue sarcoma in pediatric populations characterized by dysregulated myogenesis and limited treatment options. Notably, fusion negative RMS (FN-RMS) constitutes the predominant subtype in pediatric patients and commonly harbors RAS mutations, resulting in ...
ORGANISM(S): Mus musculus (Mouse) 
2026-10-19 | PXD056474 | Pride
Rhabdomyosarcoma  skeletal muscle  mical2 
UnknownMICAL2 Promotes Pancreatic Cancer Growth and Metastasis.
Not available
S-EPMC11907191 | biostudies-literature
GenomicsUnraveling the distinct role of MICAL2 in skeletal muscle physiology and rhabdomyosarcoma tumor progression
Unraveling the distinct role of MICAL2 in skeletal muscle physiology and rhabdomyosarcoma tumor progression
PRJNA1165673 | ENA
UnknownMICAL2 is essential for myogenic lineage commitment.
Not available
S-EPMC7434877 | biostudies-literature
GenomicsMICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis
MICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis
PRJNA1161787 | ENA
TranscriptomicsUnraveling the distinct role of MICAL2 in skeletal muscle physiology and rhabdomyosarcoma tumor progression
Rhabdomyosarcoma (RMS) is a prevalent soft tissue sarcoma in pediatric populations, characterized by dysregulated myogenesis and limited treatment options. MICAL2, a protein implicated in cancer progression, has emerged as a potential therapeutic target due to its role in modulating cellular behavio...
ORGANISM(S): Mus musculus 
2026-09-24 | GSE278087 | GEO
GenomicsMICAL2 Is a Super Enhancer Associated Gene that Promotes Pancreatic Cancer Growth and Metastasis
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers and thus identifying more effective therapies is a major unmet need. In this study we characterized the super enhancer (SE) landscape of human PDAC to identify novel, potentially targetable, drivers of the disease. Ou...
ORGANISM(S): Homo sapiens 
2024-12-11 | GSE277337 | GEO
GenomicsMICAL2 as a Key Effector of β-Catenin Signaling Driving Melanoma Progression and Therapeutic Resistance
MICAL2 as a Key Effector of β-Catenin Signaling Driving Melanoma Progression and Therapeutic Resistance
PRJNA1329336 | ENA
TranscriptomicsMICAL2 as a Key Effector of β-Catenin Signaling Driving Melanoma Progression and Therapeutic Resistance
β-catenin plays a pivotal role in oncogenesis through its involvement in cell-cell adhesion, Wnt signaling, and transcriptional regulation. Dysregulation of β-catenin contributes to tumorigenesis by promoting proliferation, bypassing senescence, and enhancing migration and invasion. In melanoma, how...
ORGANISM(S): Mus musculus 
2026-10-01 | GSE308268 | GEO
UnknownMICAL2 Facilitates Gastric Cancer Cell Migration via MRTF-A-Mediated CDC42 Activation.
Not available
S-EPMC8024553 | biostudies-literature
Sort   by:  
 Page size